Castle biosciences to release second quarter 2020 financial results and host conference call on monday, august 10, 2020
Friendswood, texas--(business wire)--castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the second quarter ended june 30, 2020, after the close of market on monday, august 10, 2020. company management will host a conference call and webcast to discuss its financial results and provide a corporate update at 4:30 p.m. eastern time on the same day. conference call and webcast details a live webcast of the conference call can be accessed at https://edge.media-server.com/mmc/p/itxfzvjn or via the webcast link on the investor relations page of the company’s website (www.castlebiosciences.com). please access the webcast at least 10 minutes before the conference call start time. an archive of the webcast will be available on the company’s website until august 31, 2020. to access the live conference call via phone, please dial 877-282-2581 from the united states and canada, or +1 470-495-9479 internationally, at least 10 minutes prior to the start of the call, using the conference id 7388802. there will be a brief question & answer session following the corporate update. about castle biosciences castle biosciences (nasdaq: cstl) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. the company currently offers tests for patients with cutaneous melanoma (decisiondx®-melanoma, decisiondx®-cmseq; www.skinmelanoma.com) and uveal melanoma (decisiondx®-um, decisiondx®-prame and decisiondx®-umseq; www.myuvealmelanoma.com), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. castle biosciences is based in friendswood, texas (houston), and has laboratory operations in phoenix, arizona. for more information, visit www.castlebiosciences.com. decisiondx-melanoma, decisiondx-cmseq, decisiondx-um, decisiondx-prame and decisiondx-umseq are trademarks of castle biosciences, inc.
CSTL Ratings Summary
CSTL Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission